Open AccessHistone methyltransferase inhibitors induce HIV-1 recovery in resting CD4+ T cells from HIV-1-infected HAART-treated patients
Author(s) -
Sophie Bouchat,
Jean-Stéphane Gatot,
Kabamba Kabeya,
Christelle Cardona,
Laurence Colin,
Georges Herbein,
Stéphane De Wit,
Nathan Clumeck,
Olivier Lambotte,
Christine Rouzioux,
Olivier Rohr,
Carine Van Lint
Publication year - 2012
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e32835535f5
Subject(s) - peripheral blood mononuclear cell , ex vivo , cd8 , methyltransferase , in vivo , vorinostat , biology , histone deacetylase inhibitor , cancer research , histone methyltransferase , immunology , virology , histone deacetylase , epigenetics , histone , immune system , in vitro , methylation , biochemistry , microbiology and biotechnology , gene
Reactivation of HIV-1 expression in persistent reservoirs together with an efficient HAART has been proposed as an adjuvant therapy aimed at reaching a functional cure for HIV. Previously, H3K9 methylation was shown to play a major role in chromatin-mediated repression of the HIV-1 promoter. Here, we evaluated the therapeutic potential of histone methyltransferase inhibitors (HMTIs) in reactivating HIV-1 from latency.